Published in Inflamm Bowel Dis on August 01, 2010
Methotrexate for Inflammatory Bowel Diseases - New Developments. Dig Dis (2016) 0.78
Methotrexate: underused and ignored? Dig Dis (2013) 0.77
Use of Methotrexate in the Treatment of Inflammatory Bowel Diseases. Inflamm Bowel Dis (2016) 0.76
Bioelectrical Stimulation for the Reduction of Inflammation in Inflammatory Bowel Disease. Clin Med Insights Gastroenterol (2015) 0.76
Genetics and Therapeutics in Pediatric Ulcerative Colitis: the Past, Present and Future. F1000Res (2016) 0.75
Involvement of Multiple Transporters-mediated Transports in Mizoribine and Methotrexate Pharmacokinetics. Pharmaceuticals (Basel) (2012) 0.75
American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum (2008) 9.94
Methotrexate for the treatment of Crohn's disease. The North American Crohn's Study Group Investigators. N Engl J Med (1995) 4.56
Comparison of the clinical efficacy and safety of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis: results of a six-month, multicenter, randomized, double-blind, controlled, phase IV trial. Arthritis Rheum (2008) 4.15
Methotrexate for rheumatoid arthritis. Suggested guidelines for monitoring liver toxicity. American College of Rheumatology. Arthritis Rheum (1994) 3.15
A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators. N Engl J Med (2000) 2.78
Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research. Ann Rheum Dis (2008) 2.61
Methotrexate induces clinical and histologic remission in patients with refractory inflammatory bowel disease. Ann Intern Med (1989) 2.55
Ulcerative colitis: female fecundity before diagnosis, during disease, and after surgery compared with a population sample. Gastroenterology (2002) 2.17
Female infertility after ileal pouch-anal anastomosis for ulcerative colitis. Dis Colon Rectum (2004) 1.87
Methotrexate in chronic active ulcerative colitis: a double-blind, randomized, Israeli multicenter trial. Gastroenterology (1996) 1.85
Methotrexate pneumonitis in rheumatoid arthritis: potential risk factors. Four case reports and a review of the literature. J Rheumatol (1987) 1.80
Recent insights in the pharmacological actions of methotrexate in the treatment of rheumatoid arthritis. Rheumatology (Oxford) (2007) 1.78
Optimal dosage and route of administration of methotrexate in rheumatoid arthritis: a systematic review of the literature. Ann Rheum Dis (2008) 1.73
Why intramuscular methotrexate may be more efficacious than oral dosing in patients with rheumatoid arthritis. Br J Rheumatol (1997) 1.68
Azathioprine or methotrexate in the treatment of patients with steroid-dependent or steroid-resistant ulcerative colitis: results of an open-label study on efficacy and tolerability in inducing and maintaining remission. Aliment Pharmacol Ther (2002) 1.66
Comparison between methotrexate and azathioprine in the treatment of chronic active Crohn's disease: a randomised, investigator-blind study. Dig Liver Dis (2003) 1.61
Methotrexate in rheumatoid arthritis. Pharmacol Rep (2006) 1.37
A comparison of low dose methotrexate bioavailability: oral solution, oral tablet, subcutaneous and intramuscular dosing. J Rheumatol (1993) 1.35
6-mercaptopurine or methotrexate added to prednisone induces and maintains remission in steroid-dependent inflammatory bowel disease. Eur J Gastroenterol Hepatol (2000) 1.34
Diagnosis and management of pouchitis. Gastroenterology (2003) 1.24
Increasing methotrexate effect with increasing dose in the treatment of resistant rheumatoid arthritis. J Rheumatol (1989) 1.23
Methotrexate: first-line or second-line immunomodulator? Eur J Gastroenterol Hepatol (2003) 1.17
Comparative tolerability of treatments for inflammatory bowel disease. Drug Saf (2000) 1.15
Pharmacokinetics of subcutaneous methotrexate. J Clin Oncol (1988) 1.11
Low dose methotrexate in the first trimester of pregnancy: results of a French collaborative study. J Rheumatol (2004) 1.09
Methotrexate in Crohn's disease: results of a randomized, double-blind, placebo-controlled trial. Hepatogastroenterology (1999) 1.03
Pharmacokinetics of methotrexate administered by intramuscular and subcutaneous injections in patients with rheumatoid arthritis. Arthritis Rheum (1990) 1.02
Hepatic effects of long-term methotrexate use in the treatment of inflammatory bowel disease. Am J Gastroenterol (2000) 0.97
Methotrexate for induction of remission in refractory Crohn's disease. Cochrane Database Syst Rev (2005) 0.96
Methotrexate in chronic active Crohn's disease: a double-blind, randomized, Israeli multicenter trial. Am J Gastroenterol (1997) 0.94
The efficacy of methotrexate for maintaining remission in inflammatory bowel disease. Aliment Pharmacol Ther (2002) 0.93
The role of subcutaneous administration of methotrexate in children with juvenile idiopathic arthritis who have failed oral methotrexate. J Rheumatol (2004) 0.93
Lack of correlation between pharmacokinetics and efficacy of low dose methotrexate in patients with rheumatoid arthritis. J Rheumatol (1995) 0.92
Bioavailability of oral vs. subcutaneous low-dose methotrexate in patients with Crohn's disease. Aliment Pharmacol Ther (2003) 0.92
Oral methotrexate in ulcerative colitis. Aliment Pharmacol Ther (2005) 0.91
Methotrexate following unsuccessful thiopurine therapy in pediatric Crohn's disease. Am J Gastroenterol (2007) 0.91
Low-dose oral methotrexate in refractory inflammatory bowel disease. Dig Dis Sci (1993) 0.90
Methotrexate bioavailability after oral and intramuscular administration in children. J Pediatr (1987) 0.90
Experience with the use of low-dose methotrexate for inflammatory bowel disease. Eur J Gastroenterol Hepatol (2004) 0.87
Splitting high-dose oral methotrexate improves bioavailability: a pharmacokinetic study in patients with rheumatoid arthritis. J Rheumatol (2006) 0.87
The absorption of low-dose methotrexate in patients with inflammatory bowel disease. Aliment Pharmacol Ther (1997) 0.87
Methotrexate for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev (2009) 0.87
A randomized dose-response and pharmacokinetic study of methotrexate for refractory inflammatory Crohn's disease and ulcerative colitis. Aliment Pharmacol Ther (1999) 0.86
Monitoring liver function during methotrexate therapy for psoriasis: are routine biopsies really necessary? Am J Clin Dermatol (2005) 0.84
Efficacy of methotrexate in Crohn's disease and ulcerative colitis patients unresponsive or intolerant to azathioprine /mercaptopurine. Aliment Pharmacol Ther (2009) 0.83
A single center experience of methotrexate in the treatment of Crohn's disease and ulcerative colitis: a case for subcutaneous administration. J Gastroenterol Hepatol (2007) 0.83
Methotrexate for induction of remission in ulcerative colitis. Cochrane Database Syst Rev (2007) 0.83
Efficacy of methotrexate in pediatric Crohn's disease: a French multicenter study. Inflamm Bowel Dis (2006) 0.82
Efficacy of parenteral methotrexate in refractory Crohn's disease. Aliment Pharmacol Ther (2001) 0.81
Methotrexate for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev (2009) 0.80
Methotrexate treatment in pediatric Crohn disease patients intolerant or resistant to purine analogues. J Pediatr Gastroenterol Nutr (2009) 0.79
Methotrexate in ulcerative colitis. Aliment Pharmacol Ther (2003) 0.77
Linking long-term dietary patterns with gut microbial enterotypes. Science (2011) 17.30
Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med (2005) 14.50
Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA (2006) 9.53
Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis. Nat Med (2013) 9.44
Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment. Genome Biol (2012) 5.66
The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology (2002) 4.98
Sampling and pyrosequencing methods for characterizing bacterial communities in the human gut using 16S sequence tags. BMC Microbiol (2010) 4.97
Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med (2013) 4.75
Ustekinumab induction and maintenance therapy in refractory Crohn's disease. N Engl J Med (2012) 4.41
Vedolizumab as induction and maintenance therapy for Crohn's disease. N Engl J Med (2013) 3.98
Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab. Gastroenterology (2009) 3.73
Initiation of tumor necrosis factor-α antagonists and the risk of hospitalization for infection in patients with autoimmune diseases. JAMA (2011) 3.58
Insulin therapy and colorectal cancer risk among type 2 diabetes mellitus patients. Gastroenterology (2004) 3.57
The human gut virome: inter-individual variation and dynamic response to diet. Genome Res (2011) 3.32
Efficacy of anti-tumor necrosis factor therapy in patients with ulcerative colitis. Am J Gastroenterol (2002) 3.01
Possible association between isotretinoin and inflammatory bowel disease. Am J Gastroenterol (2006) 2.97
Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Gastroenterology (2011) 2.96
Risks and benefits of infliximab for the treatment of Crohn's disease. Clin Gastroenterol Hepatol (2006) 2.88
Mortality associated with medical therapy versus elective colectomy in ulcerative colitis: a cohort study. Ann Intern Med (2014) 2.73
Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: a meta-analysis. Clin Gastroenterol Hepatol (2009) 2.72
Rosiglitazone for active ulcerative colitis: a randomized placebo-controlled trial. Gastroenterology (2007) 2.55
Rapid evolution of the human gut virome. Proc Natl Acad Sci U S A (2013) 2.53
Association between vaccination for herpes zoster and risk of herpes zoster infection among older patients with selected immune-mediated diseases. JAMA (2012) 2.51
Use of abdominopelvic computed tomography in emergency departments and rates of urgent diagnoses in Crohn's disease. Clin Gastroenterol Hepatol (2011) 2.40
The risk of mortality in patients with psoriasis: results from a population-based study. Arch Dermatol (2007) 2.32
Incidence and mortality of colorectal adenocarcinoma in persons with inflammatory bowel disease from 1998 to 2010. Gastroenterology (2012) 2.26
Development of an internet-based cohort of patients with inflammatory bowel diseases (CCFA Partners): methodology and initial results. Inflamm Bowel Dis (2012) 2.23
Development of the Crohn's disease digestive damage score, the Lémann score. Inflamm Bowel Dis (2010) 2.20
Incidence and risk factors for herpes zoster among patients with inflammatory bowel disease. Clin Gastroenterol Hepatol (2006) 2.16
Increased risk for demyelinating diseases in patients with inflammatory bowel disease. Gastroenterology (2005) 2.15
Rates of malignancy associated with juvenile idiopathic arthritis and its treatment. Arthritis Rheum (2012) 2.15
Association of 6-thioguanine nucleotide levels and inflammatory bowel disease activity: a meta-analysis. Gastroenterology (2006) 2.14
Initiation of anti-TNF therapy and the risk of optic neuritis: from the safety assessment of biologic ThERapy (SABER) Study. Am J Ophthalmol (2012) 2.14
Conjugated linoleic acid modulates immune responses in patients with mild to moderately active Crohn's disease. Clin Nutr (2012) 2.11
AGA medical position statement on the diagnosis and management of colorectal neoplasia in inflammatory bowel disease. Gastroenterology (2010) 2.09
An optimized patient-reported ulcerative colitis disease activity measure derived from the Mayo score and the simple clinical colitis activity index. Inflamm Bowel Dis (2014) 2.05
Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn's disease. Gastroenterology (2005) 2.05
Risks of herpes zoster in patients with rheumatoid arthritis according to biologic disease-modifying therapy. Arthritis Care Res (Hoboken) (2015) 2.03
Corticosteroids and immunomodulators: postoperative infectious complication risk in inflammatory bowel disease patients. Gastroenterology (2003) 1.94
Trends in the use of biologic agents among rheumatoid arthritis patients enrolled in the US medicare program. Arthritis Care Res (Hoboken) (2013) 1.92
Risk of kidney injury following oral phosphosoda bowel preparations. J Am Soc Nephrol (2007) 1.89
Renal function after orthotopic liver transplantation is predicted by duration of pretransplantation creatinine elevation. Liver Transpl (2005) 1.87
LRRK2 is involved in the IFN-gamma response and host response to pathogens. J Immunol (2010) 1.85
Cohort study of pioglitazone and cancer incidence in patients with diabetes. Diabetes Care (2011) 1.83
Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS). Gut (2011) 1.80
Time trends in therapies and outcomes for adult inflammatory bowel disease, Northern California, 1998-2005. Gastroenterology (2009) 1.74
The risk of developing Crohn's disease after an appendectomy: a meta-analysis. Am J Gastroenterol (2008) 1.74
Incidence and prevalence of inflammatory bowel disease in a Northern California managed care organization, 1996-2002. Am J Gastroenterol (2008) 1.72
Crohn's disease patients' risk-benefit preferences: serious adverse event risks versus treatment efficacy. Gastroenterology (2007) 1.71
Tacrolimus for the treatment of fistulas in patients with Crohn's disease: a randomized, placebo-controlled trial. Gastroenterology (2003) 1.70
Association between longer therapy with thiazolidinediones and risk of bladder cancer: a cohort study. J Natl Cancer Inst (2012) 1.69
Cancer incidence in The Health Improvement Network. Pharmacoepidemiol Drug Saf (2009) 1.65
Archaea and fungi of the human gut microbiome: correlations with diet and bacterial residents. PLoS One (2013) 1.64
Validity of The Health Improvement Network (THIN) for epidemiologic studies of hepatitis C virus infection. Pharmacoepidemiol Drug Saf (2009) 1.61
American gastroenterological association consensus development conference on the use of biologics in the treatment of inflammatory bowel disease, June 21-23, 2006. Gastroenterology (2007) 1.60
Hypervariable loci in the human gut virome. Proc Natl Acad Sci U S A (2012) 1.58
Prevention and treatment of osteoporosis in inflammatory bowel disease. Inflamm Bowel Dis (2006) 1.58
Impact of hospital volume on postoperative morbidity and mortality following a colectomy for ulcerative colitis. Gastroenterology (2008) 1.56
A systematic review of factors that contribute to hepatosplenic T-cell lymphoma in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol (2010) 1.55
A meta-analysis of the placebo rates of remission and response in clinical trials of active Crohn's disease. Gastroenterology (2004) 1.51
Anti-TNF antibodies for Crohn's disease--in pursuit of the perfect clinical trial. N Engl J Med (2007) 1.50
Structure-constrained sparse canonical correlation analysis with an application to microbiome data analysis. Biostatistics (2012) 1.49
Influence of alcohol use, race, and viral coinfections on spontaneous HCV clearance in a US veteran population. Hepatology (2004) 1.49
Communication outcomes in audiologic reporting. J Am Acad Audiol (2011) 1.48
Association between the initiation of anti-tumor necrosis factor therapy and the risk of herpes zoster. JAMA (2013) 1.45
Rates of hospitalized bacterial infection associated with juvenile idiopathic arthritis and its treatment. Arthritis Rheum (2012) 1.43
Real-time tool to display the predicted disease course and treatment response for children with Crohn's disease. Inflamm Bowel Dis (2010) 1.42
Role of thiopurine and anti-TNF therapy in lymphoma in inflammatory bowel disease. Am J Gastroenterol (2011) 1.39
A meta-analysis of the placebo rates of remission and response in clinical trials of active ulcerative colitis. Gastroenterology (2006) 1.39
Quality indicators for inflammatory bowel disease: development of process and outcome measures. Inflamm Bowel Dis (2013) 1.33
The impact of increased body mass index on the clinical course of Crohn's disease. Clin Gastroenterol Hepatol (2006) 1.32
Study design for a comprehensive assessment of biologic safety using multiple healthcare data systems. Pharmacoepidemiol Drug Saf (2011) 1.30
Incidence, prevalence, and time trends of pediatric inflammatory bowel disease in Northern California, 1996 to 2006. J Pediatr (2010) 1.30
Trends in hospitalization rates for inflammatory bowel disease in the United States. Clin Gastroenterol Hepatol (2007) 1.30
Potential association between the oral tetracycline class of antimicrobials used to treat acne and inflammatory bowel disease. Am J Gastroenterol (2010) 1.28
Dietary patterns and self-reported associations of diet with symptoms of inflammatory bowel disease. Dig Dis Sci (2012) 1.27
Occurrence of colon ischemia in relation to irritable bowel syndrome. Am J Gastroenterol (2004) 1.25
Long-term infliximab maintenance therapy for ulcerative colitis: the ACT-1 and -2 extension studies. Inflamm Bowel Dis (2011) 1.22
Transition of adolescents with inflammatory bowel disease from pediatric to adult care: a survey of adult gastroenterologists. J Pediatr Gastroenterol Nutr (2009) 1.22
A pooled analysis of infections, malignancy, and mortality in infliximab- and immunomodulator-treated adult patients with inflammatory bowel disease. Am J Gastroenterol (2012) 1.22
Outcome of surgical versus percutaneous drainage of abdominal and pelvic abscesses in Crohn's disease. Am J Gastroenterol (2006) 1.21
The inflammatory bowel diseases and ambient air pollution: a novel association. Am J Gastroenterol (2010) 1.19
A tool kit for quantifying eukaryotic rRNA gene sequences from human microbiome samples. Genome Biol (2012) 1.17
The London position statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organisation: safety. Am J Gastroenterol (2011) 1.15
Fontolizumab in moderate to severe Crohn's disease: a phase 2, randomized, double-blind, placebo-controlled, multiple-dose study. Inflamm Bowel Dis (2010) 1.15
Abatacept for Crohn's disease and ulcerative colitis. Gastroenterology (2012) 1.15
IBD Around the world: comparing the epidemiology, diagnosis, and treatment: proceedings of the World Digestive Health Day 2010--Inflammatory Bowel Disease Task Force meeting. Inflamm Bowel Dis (2011) 1.14
Reliability and initial validation of the ulcerative colitis endoscopic index of severity. Gastroenterology (2013) 1.14
Patient perceptions of the risks and benefits of infliximab for the treatment of inflammatory bowel disease. Inflamm Bowel Dis (2008) 1.13
Are adult patients more tolerant of treatment risks than parents of juvenile patients? Risk Anal (2008) 1.13
Chronic proton pump inhibitor therapy and the risk of colorectal cancer. Gastroenterology (2007) 1.13
Type 2 diabetes mellitus and the risk of colorectal cancer. Clin Gastroenterol Hepatol (2005) 1.12
Fungi of the murine gut: episodic variation and proliferation during antibiotic treatment. PLoS One (2013) 1.11
Are gastroenterologists less tolerant of treatment risks than patients? Benefit-risk preferences in Crohn's disease management. J Manag Care Pharm (2010) 1.11
Validation of The Health Improvement Network (THIN) database for epidemiologic studies of chronic kidney disease. Pharmacoepidemiol Drug Saf (2011) 1.11
Perioperative treatment with infliximab in patients with Crohn's disease and ulcerative colitis is not associated with an increased rate of postoperative complications. J Gastrointest Surg (2008) 1.09
The impact of bariatric surgery on menstrual patterns. Obes Surg (2006) 1.08
Prevalence of colorectal cancer surveillance for ulcerative colitis in an integrated health care delivery system. Gastroenterology (2010) 1.07